Bovine Mastitis Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Bovine Mastitis Market
The bovine mastitis market size was valued at USD 1.23 billion in 2019, and the market is now projected to grow from USD 1.23 billion in 2019 to USD 1.84 billion by 2032, exhibiting a CAGR of 5.2% during the forecast period of 2019-2032.
Pandemic has now not considerably impacted the uptake of bovine mastitis market growth, in step with a record by means of Zoetis in April 2020. The supply chain has now not been directly affected, and corporations are in near touch with the US FDA to tell them of shortages or manufacturing delays. Animal healthcare associations and countrywide government are operating collectively to preserve a network of shipping services, implement inexperienced lanes, and make certain the provision of products and important offerings, which includes veterinary drugs.
The veterinary market is anticipated to significantly benefit from new developments, with veterinary groups specializing in product launches and strategic mergers to save you mastitis. Merck and Co., Inc. Launched Shut Out, an antibiotic-loose teat sealant in February 2020, to prevent intramammary infections, which include mastitis in livestock. These new product introductions intention to fill the clinical gap due to antibiotics and different drugs for efficient remedy of mastitis, making sure a synergistic effect in the enterprise.
Dairy animal farmers international are disturbing powerful treatment for fatal mammary gland infections due to rising economic burdens and antibiotic resistance. Biopharmaceutical organizations are specializing in developing non-antibiotic remedies for this situation. Ireland-primarily based Westway Health is developing PanaMast, a singular non-antibiotic remedy. The developing attention of antibiotic resistance among dairy farms is riding call for novel procedures and merchandise. Research projects aimed at introducing novel healing procedures are anticipated to drive call for drugs in remedy all through the forecast period.
Comprehensive Analysis of Bovine Mastitis Market
The market for bovine mastitis is divided into clinical and sub-clinical segments, with clinical mastitis dominating due to increasing dairy herd size and incidence cases. The demand for treatment, availability of drugs, and growing awareness are driving global adoption. The sub-clinical segment is expected to experience a significant CAGR due to rising awareness among cattle farmers about early detection and treatment. Antibiotics are the dominant product segment, showing clinical effectiveness in controlling mastitis in dairy cattle. The market is divided into intramammary and systemic administration routes, with the intramammary segment holding the highest market share and experiencing significant growth. The dry period segment has the highest market share, driven by increased awareness about mastitis infections and the shift towards selective dry cow therapy. The demand for teat sealants during the dry period is expected to increase due to increased focus on teat sealant launches and initiatives promoting their use among dairy farmers.
The North America region lead the bovine mastitis market share by benefitting a market size of USD 0.40 billion in 2019 due to huge use of intramammary infusion merchandise and the presence of main gamers providing a whole lot of mastitis control merchandise. The European marketplace is expected to grow at a sizeable CAGR due to elevated collaboration among key players.
The bovine mastitis market is consolidated by fundamental corporations in developed and emerging countries, with Merck and Co., Inc., Zoetis, and Boehringer Ingelheim International GmbH keeping a dominant percentage. Factors along with large manufacturing sites and a focal point on modern products are expected to preserve their position. Other key players like Elanco, Ceva, Bayer AG, and West Way Health are planning to reinforce their presence by way of investing in novel cures and collaborations with research groups. Key agencies expected consist of Zoetis, Merck and Co., Inc., International GmbH, Bayer AG, Elanco, Ceva, and West Way Health.
Boehringer Ingelheim has introduced blue Ubroseal internal teat sealant to its dairy mastitis portfolio to save you new intramammary infections all through the dry duration.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2016-2027
Base Year 2019
Forecast Period 2020-2027
Historical Period 2016-2018
Unit Value (USD billion)
SegmentationBy Type
Clinical
Sub-clinical
By Product
Antibiotics
Others
By Route of Administration
Intramammary
Systemic
By Therapy
Lactation Period
Dry Period
Antibiotics
Teat Sealants
By Geography
North America (U.S. and Canada)
Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)
Rest of the World
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 4. Key Insights
- 4.1. New Developments – Bovine Mastitis Product
- 4.2. Incidence of Clinical Mastitis Key Countries/Sub-region-2019
- 4.3. Key Products/ Brands, Key Players
- 4.4. Number of Milk Cows- Key Countries/Sub-region -2019
- 4.5. Veterinary Drugs Market: Overview
- 4.6. Product Overview: Teat Sealants for Mastitis Treatment (Key Brands/ Key Players, 2019)
- 4.7. Pricing Analysis, 2019 (Key Brands/ Key Countries)
- 4.8. Key Developments – Mergers, Acquisitions, and Partnerships
- 5. Global Bovine Mastitis Market Analysis, Insights and Forecast 2016-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Type
- 5.2.1. Clinical Mastitis
- 5.2.2. Sub-clinical Mastitis
- 5.3. Market Analysis, Insights and Forecast – By Product
- 5.3.1. Antibiotics
- 5.3.2. Others
- 5.4. Market Analysis, Insights and Forecast – By Route of Administration
- 5.4.1. Intramammary
- 5.4.2. Systemic
- 5.5. Market Analysis, Insights and Forecast – By Therapy
- 5.5.1. Lactating Period
- 5.5.2. Dry Period
- 5.5.2.1. Antibiotics
- 5.5.2.2. Teat sealants
- 5.6. Market Analysis, Insights and Forecast – By Region
- 5.6.1. North America
- 5.6.2. Europe
- 5.6.3. Asia Pacific
- 5.6.4. Rest of the World
- 6. North America Bovine Mastitis Market Analysis, Insights and Forecast 2016-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Type
- 6.2.1. Clinical Mastitis
- 6.2.2. Sub-clinical Mastitis
- 6.3. Market Analysis, Insights and Forecast – By Product
- 6.3.1. Antibiotics
- 6.3.2. Others
- 6.4. Market Analysis, Insights and Forecast – By Route of Administration
- 6.4.1. Intramammary
- 6.4.2. Systemic
- 6.5. Market Analysis, Insights and Forecast – By Therapy
- 6.5.1. Lactating Period
- 6.5.2. Dry Period
- 6.5.2.1. Antibiotics
- 6.5.2.2. Teat sealants
- 6.6. Market Analysis, Insights and Forecast – By Country
- 6.6.1. U.S.
- 6.6.2. Canada
- 7. Europe Bovine Mastitis Market Analysis, Insights and Forecast 2016-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Type
- 7.2.1. Clinical Mastitis
- 7.2.2. Sub-clinical Mastitis
- 7.3. Market Analysis, Insights and Forecast – By Product
- 7.3.1. Antibiotics
- 7.3.2. Others
- 7.4. Market Analysis, Insights and Forecast – By Route of Administration
- 7.4.1. Intramammary
- 7.4.2. Systemic
- 7.5. Market Analysis, Insights and Forecast – By Therapy
- 7.5.1. Lactating Period
- 7.5.2. Dry Period
- 7.5.2.1. Antibiotics
- 7.5.2.2. Teat sealants
- 7.6. Market Analysis, Insights and Forecast – By Country/Sub-region
- 7.6.1. U.K.
- 7.6.2. Germany
- 7.6.3. France
- 7.6.4. Spain
- 7.6.5. Italy
- 7.6.6. Scandinavia
- 7.6.7. Rest of Europe
- 8. Asia Pacific Bovine Mastitis Market Analysis, Insights and Forecast 2016-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Type
- 8.2.1. Clinical Mastitis
- 8.2.2. Sub-clinical Mastitis
- 8.3. Market Analysis, Insights and Forecast – By Product
- 8.3.1. Antibiotics
- 8.3.2. Others
- 8.4. Market Analysis, Insights and Forecast – By Route of Administration
- 8.4.1. Intramammary
- 8.4.2. Systemic
- 8.5. Market Analysis, Insights and Forecast – By Therapy
- 8.5.1. Lactating Period
- 8.5.2. Dry Period
- 8.5.2.1. Antibiotics
- 8.5.2.2. Teat sealants
- 8.6. Market Analysis, Insights and Forecast – By Country/sub-region
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. Australia
- 8.6.5. Southeast Asia
- 8.6.6. Rest of Asia Pacific
- 9. Rest of the World Bovine Mastitis Market Analysis, Insights and Forecast 2016-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Type
- 9.2.1. Clinical Mastitis
- 9.2.2. Sub-clinical Mastitis
- 9.3. Market Analysis, Insights and Forecast – By Product
- 9.3.1. Antibiotics
- 9.3.2. Others
- 9.4. Market Analysis, Insights and Forecast – By Route of Administration
- 9.4.1. Intramammary
- 9.4.2. Systemic
- 9.5. Market Analysis, Insights and Forecast – By Therapy
- 9.5.1. Lactating Period
- 9.5.2. Dry Period
- 9.5.2.1. Antibiotics
- 9.5.2.2. Teat sealants
- 10. Competitive Analysis
- 10.1. Key Industry Developments
- 10.2. Global Market Share Analysis (2019)
- 10.3. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
- 10.3.1. Zoetis
- 10.3.1.1. Overview,
- 10.3.1.2. Products & services,
- 10.3.1.3. SWOT analysis,
- 10.3.1.4. Recent developments,
- 10.3.1.5. strategies,
- 10.3.1.6. financials (based on availability)
- 10.3.2. Merck & Co., Inc. (MSD Animal Health)
- 10.3.2.1. Overview,
- 10.3.2.2. Products & services,
- 10.3.2.3. SWOT analysis,
- 10.3.2.4. Recent developments,
- 10.3.2.5. strategies,
- 10.3.2.6. financials (based on availability)
- 10.3.3. Boehringer Ingelheim International GmbH
- 10.3.3.1. Overview,
- 10.3.3.2. Products & services,
- 10.3.3.3. SWOT analysis,
- 10.3.3.4. Recent developments,
- 10.3.3.5. strategies,
- 10.3.3.6. financials (based on availability)
- 10.3.4. Boehringer Ingelheim International GmbH
- 10.3.4.1. Overview,
- 10.3.4.2. Products & services,
- 10.3.4.3. SWOT analysis,
- 10.3.4.4. Recent developments,
- 10.3.4.5. strategies,
- 10.3.4.6. financials (based on availability)
- 10.3.5. Elanco
- 10.3.5.1. Overview,
- 10.3.5.2. Products & services,
- 10.3.5.3. SWOT analysis,
- 10.3.5.4. Recent developments,
- 10.3.5.5. strategies,
- 10.3.5.6. financials (based on availability)
- 10.3.6. Ceva
- 10.3.6.1. Overview,
- 10.3.6.2. Products & services,
- 10.3.6.3. SWOT analysis,
- 10.3.6.4. Recent developments,
- 10.3.6.5. strategies,
- 10.3.6.6. financials (based on availability)
- 10.3.7. West Way Health.
- 10.3.7.1. Overview,
- 10.3.7.2. Products & services,
- 10.3.7.3. SWOT analysis,
- 10.3.7.4. Recent developments,
- 10.3.7.5. strategies,
- 10.3.7.6. financials (based on availability)
- 10.3.8. Others
- 10.3.8.1. Overview,
- 10.3.8.2. Products & services,
- 10.3.8.3. SWOT analysis,
- 10.3.8.4. Recent developments,
- 10.3.8.5. strategies,
- 10.3.8.6. financials (based on availability)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook